Related Experiment Video
Updated: Jul 13, 2026
12:25
Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
Published on: January 7, 2014
15.2K
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Rochelle Bagatell1, Julie R Park2, Sahaja Acharya3
11Abramson Cancer Center at the University of Pennsylvania | Children's Hospital of Philadelphia.
Journal of the National Comprehensive Cancer Network : JNCCN
|August 16, 2024
Summary
This summary introduces the first National Comprehensive Cancer Network (NCCN) Guidelines for Neuroblastoma, offering expert recommendations for diagnosing and treating this common childhood cancer.
Area of Science:
- Pediatric Oncology
- Cancer Therapeutics
- Clinical Guidelines
Background:
- Neuroblastoma is the most frequent extracranial solid tumor in children.
- Effective management requires a multidisciplinary approach.
- Clinical heterogeneity necessitates tailored treatment strategies.
Purpose of the Study:
- To present the inaugural version of the NCCN Guidelines for Neuroblastoma.
- To provide evidence-based recommendations for neuroblastoma care.
- To guide clinicians in diagnosis, risk classification, and treatment selection.
Main Methods:
- Development by the NCCN Neuroblastoma Panel, a multidisciplinary expert group.
- Inclusion of pediatric oncologists, radiologists, pathologists, surgeons, and radiation oncologists.
- Consensus-based recommendations derived from expert review.
Main Results:
- The guidelines offer comprehensive recommendations for neuroblastoma management.
- They cover diagnosis, risk stratification, and treatment options.
- The recommendations are intended for clinicians treating pediatric patients.
Conclusions:
- The NCCN Guidelines for Neuroblastoma provide a crucial resource for clinicians.
- These guidelines aim to standardize and optimize care for this pediatric malignancy.
- The multidisciplinary development ensures a holistic approach to neuroblastoma treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...